Navigation Links
Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
Date:11/11/2013

SHELTON, Conn., Nov. 11, 2013 /PRNewswire/ -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

Stifel and Piper Jaffray will act as joint book-running managers for the offering. Canaccord Genuity, Needham & Company and Janney Montgomery Scott will act as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, and from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by calling (800) 747-3924 or by emailing prospectus@pjc.com.  

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cara Therapeutics  

Cara Therapeutics is a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.


'/>"/>
SOURCE Cara Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
2. Echo Therapeutics Announces Third Quarter 2013 Financial Results
3. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
4. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
5. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
6. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
7. Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
8. Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity
9. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
10. Mast Therapeutics Reports Third Quarter 2013 Financial Results
11. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Tillotts Pharma is strengthening ... Berlin office was opened in January 2017 ... portfolio includes Entocort ® for the treatment of ... ulcerative colitis, and VistaPrep ® for bowel preparation ... pharmaceutical company focused on the treatment of gastrointestinal (GI) ...
(Date:2/23/2017)... 23, 2017  Spheryx, Inc. will present ... at PittCon 2017 Conference and Exposition at ... world,s largest annual premier conference and exposition ... array of industry, academic and government communities ... food safety, environmental, bioterrorism and other emerging ...
(Date:2/23/2017)... 23, 2017 The U.S. cannabis market ... for recreational use in 2016. According to a new report ... worth an estimated $7.2 billion in 2016 and is projected ... While adult recreational sales are projected to jump from $2.6 ... 25% CAGR. The market may grow faster as the estimate ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in ... the month of February, patients who visit Hamlin Dental Group will receive a ticket ... two at the Cheesecake Factory. , Tickets are available for routine dental visits ...
(Date:2/23/2017)... Henderson, Nevada (PRWEB) , ... February 23, 2017 , ... ... Eastern Avenue in Henderson, NV 89052. Dr. Mahon was named a 2017 Top Patient ... Local Doctors is an online directory that recognizes local physicians and dentists who ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Top cosmetic ... Smiling Patriot program today with a new Indiegogo campaign . Individuals are ... homeless veterans in the Los Angeles area, either as a participating patient or through ...
(Date:2/23/2017)... Va. (PRWEB) , ... February 23, 2017 , ... ... or problems. He has also continued to spiritually evolve, which is the purpose of ... book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers ...
Breaking Medicine News(10 mins):